Lannett Company, Inc. LCI

Set alert

Price alert · LCI

All alert types
0.69 +0.69 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
7.38M
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-0.13
Beta
0.95
Short ratio
29.56
Inst. own
38.93%
Dividend
0.00
Ex-div date
Earnings
May 3, 2023
50-d avg
1.30
200-d avg
2.00
1y target
4.00

2Y chart

Chart tools
Interval

Events in this range
  • Feb 3, 2022Earnings: —; estimate -1.28; surprise —%
  • May 4, 2022Earnings: —; estimate -1.72; surprise —%
  • Aug 24, 2022Earnings: —; estimate -1.84; surprise —%
  • Nov 2, 2022Earnings: —; estimate -1.84; surprise —%
  • Feb 1, 2023Earnings: —; estimate -1.64; surprise —%
  • Feb 7, 2023Split: 1 for 4
  • May 3, 2023Earnings: —; estimate -1.56; surprise —%
Signals (74)
NameDateAgo
MACD: Buy SignalMay 4, 20233 years ago
MACD: Sell SignalApr 4, 20233 years ago
RSI: OversoldApr 4, 20233 years ago
MACD: Buy SignalMar 30, 20233 years ago
RSI: OversoldMar 16, 20233 years ago
SMA: BearishFeb 22, 20233 years ago
SMA: BearishFeb 17, 20233 years ago
MACD: Sell SignalFeb 16, 20233 years ago
MACD: Buy SignalFeb 3, 20233 years ago
SMA: BullishFeb 2, 20233 years ago
SMA: BullishFeb 2, 20233 years ago
SMA: BearishJan 26, 20233 years ago
SMA: BearishJan 26, 20233 years ago
MACD: Sell SignalJan 26, 20233 years ago
MACD: Buy SignalJan 17, 20233 years ago
SMA: BullishJan 11, 20233 years ago
SMA: BearishJan 6, 20233 years ago
SMA: BullishJan 4, 20233 years ago
SMA: BullishJan 4, 20233 years ago
SMA: BearishDec 29, 20223 years ago

Newest 20 of 74.

Key statistics

Market cap
7.38M
Enterprise value
586.34M
Trailing P/E
0.00
Forward P/E
-0.13
PEG ratio
0.00
Price / sales
0.02
Price / book
0.00
EPS (TTM)
-19.14
Beta
0.95
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-62.40%
Revenue (TTM)
308.52M
Revenue growth
-6.50%
Free cash flow
19.33M
Total cash
55.85M
Total debt
635.37M
Return on equity
0.00%
Shares outstanding
10.77M
Short % of float
13.28%
50-day average
1.30
200-day average
2.00

Earnings

LCI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 3, 2023Mar 1, 2023-1.56———
Feb 1, 2023Dec 1, 2022-1.64———
Nov 2, 2022Sep 1, 2022-1.84———
Aug 24, 2022Jun 1, 2022-1.84———
May 4, 2022Mar 1, 2022-1.72———
Feb 3, 2022Dec 1, 2021-1.28———

Upgrades / downgrades

LCI analyst upgrades and downgrades
DateFirmActionFromTo
Aug 31, 2021Roth Capitalmain—Neutral
Jun 10, 2021Roth Capitalmain—Neutral
Sep 18, 2019SunTrust Robinson Humphreymain—Hold
Aug 29, 2019SunTrust Robinson Humphreymain—Hold
Mar 20, 2019SunTrust Robinson Humphreyinit—Hold
Aug 21, 2018BMO CapitalmainMarket PerformMarket Perform

About Lannett Company, Inc.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.

Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Country
United States
Website
lannett.com

News

Your note

Sign in to keep a note on LCI — it syncs with the Stock Master app.

Insider holders

LCI insider holders
InsiderRelationLatest transactionDateShares held
ABT JOHN MOfficerPurchaseFeb 9, 2022128,815
CHAPMAN JOHN CDirectorPurchaseNov 16, 2022174,324
CREW TIMOTHY CChief Executive OfficerPurchaseNov 9, 2022604,291
DRABIK DAVID ADirectorStock Award(Grant)Aug 30, 2021108,332
EHLINGER ROBERTFormerStock Award(Grant)Dec 2, 2021105,491
FARBER JEFFREYDirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseMar 16, 20222,152,450

Institution ownership

LCI institution ownership
Holder% heldSharesValueReported
Telemus Capital, LLC4.47%1,927,1991.32MMar 30, 2023
Renaissance Technologies, LLC1.13%487,620334.26KDec 30, 2022
Shaw D.E. & Co., Inc.0.70%302,532207.38KDec 30, 2022
Vanguard Group, Inc. (The)0.43%185,455127.13KDec 30, 2022
Staley Capital Advisers, Inc.0.36%153,786105.42KDec 30, 2022
Blackrock Inc.0.33%143,42198.31KDec 30, 2022

Fund ownership

LCI fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund0.29%122,93684.27KSep 29, 2022
Invesco ETF Tr-Invesco FTSE RAFI US 1500 Small-Mid ETF0.23%97,19066.62KDec 30, 2022
Fidelity Extended Market Index Fund0.13%57,03739.10KNov 29, 2022
Vanguard Total Stock Market Index Fund0.11%46,31431.75KSep 29, 2022
Bridgeway Funds Inc-Ultra Small Company Market Fund0.10%41,47528.43KSep 29, 2022
Bridge Builder Tr-Bridge Builder Small/Mid Cap Value Fd0.03%14,4259.89KSep 29, 2022